Research ExplorerPublicationsMetabolic Syndrome Negatively Impacts the Outcome of Localiz...

Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma

Standard

Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma. / Kriegmair, Maximilian Christian; Mandel, Philipp; Porubsky, Stefan; Dürr, Julia; Huck, Nina; Nuhn, Philipp; Pfalzgraf, Daniel; Michel, Maurice Stephan; Wagener, Nina.

In: DISCOV ONCOL, Vol. 8, No. 2, 04.2017, p. 127-134.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kriegmair, MC, Mandel, P, Porubsky, S, Dürr, J, Huck, N, Nuhn, P, Pfalzgraf, D, Michel, MS & Wagener, N 2017, 'Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma', DISCOV ONCOL, vol. 8, no. 2, pp. 127-134. https://doi.org/10.1007/s12672-017-0289-2

APA

Kriegmair, M. C., Mandel, P., Porubsky, S., Dürr, J., Huck, N., Nuhn, P., Pfalzgraf, D., Michel, M. S., & Wagener, N. (2017). Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma. DISCOV ONCOL, 8(2), 127-134. https://doi.org/10.1007/s12672-017-0289-2

Vancouver

Kriegmair MC, Mandel P, Porubsky S, Dürr J, Huck N, Nuhn P et al. Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma. DISCOV ONCOL. 2017 Apr;8(2):127-134. https://doi.org/10.1007/s12672-017-0289-2

Bibtex

@article{774e3b54d2c04933b90af730c1463013,
title = "Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma",
abstract = "The aim of this study was to analyze the impact of metabolic syndrome (MetS) on outcome of patients with localized renal cell carcinoma (RCC). A retrospective database was compiled consisting of 646 patients who underwent surgery for localized RCC between 2005 and 2014. A total of 439 patients were eligible for final analysis. For diagnosis of MetS, the WHO criteria of 1998 were used. Median follow-up was 32 months (ranging from 2 to 119). Kaplan-Meier and log-rank analyses were performed to compare patients with and without MetS or its components. Univariate and multivariate logistic regression identified prognostic factors for progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS). In our cohort, 9.8% (n = 43) of patients were diagnosed with MetS. There were no differences between patients with and without MetS regarding clinicopathological parameters with the exception of patients' age (p = 0.002). Kaplan-Meier and log-rank analyses revealed a shorter PFS for patients with MetS (p = 0.018), whereas no differences were found for each of the single components of MetS, namely, diabetes mellitus (DM) (p = 0.332), BMI >30 kg/m2(p = 0.753), hypertension (p = 0.451), and hypertriglyceridemia (p = 0.891). Logistic regression identified age (HR = 1.92, p = 0.03), tumor stage (HR = 4.37, p < 0.001), grading (HR = 4.57, p < 0.001), nodal status (HR = 3.73, p = 0.04), surgical margin (HR = 1.96, p = 0.04), concomitant sarcomatoid differentiation (HR = 5.06, p < 0.001), and MetS (HR = 1.98, p = 0.04) as independent factors for PFS. For CSS, only age (HR = 2.62, p = 0.035), tumor stage (HR = 3.06, p < 0.02), and grading (HR = 6.83, p < 0.001) were significant. In conclusion, patients with localized RCC and MetS show significantly reduced PFS and might profit from specific consultation and follow-up.",
keywords = "Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Kidney Neoplasms, Male, Metabolic Syndrome, Middle Aged, Neoplasm Staging, Retrospective Studies, Survival Analysis, Treatment Outcome, Journal Article",
author = "Kriegmair, {Maximilian Christian} and Philipp Mandel and Stefan Porubsky and Julia D{\"u}rr and Nina Huck and Philipp Nuhn and Daniel Pfalzgraf and Michel, {Maurice Stephan} and Nina Wagener",
year = "2017",
month = apr,
doi = "10.1007/s12672-017-0289-2",
language = "English",
volume = "8",
pages = "127--134",
journal = "DISCOV ONCOL",
issn = "1868-8497",
publisher = "SPRINGER US",
number = "2",

}

RIS

TY - JOUR

T1 - Metabolic Syndrome Negatively Impacts the Outcome of Localized Renal Cell Carcinoma

AU - Kriegmair, Maximilian Christian

AU - Mandel, Philipp

AU - Porubsky, Stefan

AU - Dürr, Julia

AU - Huck, Nina

AU - Nuhn, Philipp

AU - Pfalzgraf, Daniel

AU - Michel, Maurice Stephan

AU - Wagener, Nina

PY - 2017/4

Y1 - 2017/4

N2 - The aim of this study was to analyze the impact of metabolic syndrome (MetS) on outcome of patients with localized renal cell carcinoma (RCC). A retrospective database was compiled consisting of 646 patients who underwent surgery for localized RCC between 2005 and 2014. A total of 439 patients were eligible for final analysis. For diagnosis of MetS, the WHO criteria of 1998 were used. Median follow-up was 32 months (ranging from 2 to 119). Kaplan-Meier and log-rank analyses were performed to compare patients with and without MetS or its components. Univariate and multivariate logistic regression identified prognostic factors for progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS). In our cohort, 9.8% (n = 43) of patients were diagnosed with MetS. There were no differences between patients with and without MetS regarding clinicopathological parameters with the exception of patients' age (p = 0.002). Kaplan-Meier and log-rank analyses revealed a shorter PFS for patients with MetS (p = 0.018), whereas no differences were found for each of the single components of MetS, namely, diabetes mellitus (DM) (p = 0.332), BMI >30 kg/m2(p = 0.753), hypertension (p = 0.451), and hypertriglyceridemia (p = 0.891). Logistic regression identified age (HR = 1.92, p = 0.03), tumor stage (HR = 4.37, p < 0.001), grading (HR = 4.57, p < 0.001), nodal status (HR = 3.73, p = 0.04), surgical margin (HR = 1.96, p = 0.04), concomitant sarcomatoid differentiation (HR = 5.06, p < 0.001), and MetS (HR = 1.98, p = 0.04) as independent factors for PFS. For CSS, only age (HR = 2.62, p = 0.035), tumor stage (HR = 3.06, p < 0.02), and grading (HR = 6.83, p < 0.001) were significant. In conclusion, patients with localized RCC and MetS show significantly reduced PFS and might profit from specific consultation and follow-up.

AB - The aim of this study was to analyze the impact of metabolic syndrome (MetS) on outcome of patients with localized renal cell carcinoma (RCC). A retrospective database was compiled consisting of 646 patients who underwent surgery for localized RCC between 2005 and 2014. A total of 439 patients were eligible for final analysis. For diagnosis of MetS, the WHO criteria of 1998 were used. Median follow-up was 32 months (ranging from 2 to 119). Kaplan-Meier and log-rank analyses were performed to compare patients with and without MetS or its components. Univariate and multivariate logistic regression identified prognostic factors for progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS). In our cohort, 9.8% (n = 43) of patients were diagnosed with MetS. There were no differences between patients with and without MetS regarding clinicopathological parameters with the exception of patients' age (p = 0.002). Kaplan-Meier and log-rank analyses revealed a shorter PFS for patients with MetS (p = 0.018), whereas no differences were found for each of the single components of MetS, namely, diabetes mellitus (DM) (p = 0.332), BMI >30 kg/m2(p = 0.753), hypertension (p = 0.451), and hypertriglyceridemia (p = 0.891). Logistic regression identified age (HR = 1.92, p = 0.03), tumor stage (HR = 4.37, p < 0.001), grading (HR = 4.57, p < 0.001), nodal status (HR = 3.73, p = 0.04), surgical margin (HR = 1.96, p = 0.04), concomitant sarcomatoid differentiation (HR = 5.06, p < 0.001), and MetS (HR = 1.98, p = 0.04) as independent factors for PFS. For CSS, only age (HR = 2.62, p = 0.035), tumor stage (HR = 3.06, p < 0.02), and grading (HR = 6.83, p < 0.001) were significant. In conclusion, patients with localized RCC and MetS show significantly reduced PFS and might profit from specific consultation and follow-up.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Renal Cell

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Kidney Neoplasms

KW - Male

KW - Metabolic Syndrome

KW - Middle Aged

KW - Neoplasm Staging

KW - Retrospective Studies

KW - Survival Analysis

KW - Treatment Outcome

KW - Journal Article

U2 - 10.1007/s12672-017-0289-2

DO - 10.1007/s12672-017-0289-2

M3 - SCORING: Journal article

C2 - 28247362

VL - 8

SP - 127

EP - 134

JO - DISCOV ONCOL

JF - DISCOV ONCOL

SN - 1868-8497

IS - 2

ER -